Myriad gene patent survives challenge in Australia

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Myriad gene patent survives challenge in Australia

In a Federal Court ruling, Justice John Nicholas held that isolated genetic material is patentable in Australia

Cancer Voices of Australia had challenged Myriad Genetics’ patent on the isolated nucleic acid coding for a mutant or polymorphic BRCA1 polypeptide, arguing that the subject matter was not patentable. Section 18(1)(a) of the Patents Act states that invention must be of “a manner of manufacture within the meaning of section 6 of the Statute of Monopolies” in order to be patentable. Cancer Voices claimed that the isolated DNA and RNA were naturally occurring and thus not patentable.

Justice Nicholas disagreed, noting that the controlling case, National Research Development Corporation vs Commissioner of Patents (the NDRC case), held that this criteria is satisfied if the invention consists of an “artificially created state of affairs”, is discernible over time, and has economic significance. Even if the material is naturally occurring as Cancer Voices asserted, the endeavour required in isolating the genetic material can be understood as an artificially created state.

The other criteria of discernibility and economic significance were not at issue. Cancer Voices did not assert that the invention was not new or lacked inventive step.

The United States Supreme Court has agreed to review the patentability of the same BRCA1 as well as the BRCA2 sequences patented by Myriad, after the Court of Appeals for the Federal Circuit held that the isolated sequences were patentable under section 101. The Supreme Court is expected to issue its ruling by the end of the year.

more from across site and SHARED ros bottom lb

More from across our site

Florina Firaru discusses making new connections, the art of flower arranging, and the biggest misconception about IP
The firm, which appointed three IP partners from A&O Shearman, wants to develop a tier one practice in Europe
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck
A host of law firms from across Europe and beyond helped bring the streaming technology dispute to a close
Hugues Derème, director general of the Benelux IP Office, unveils his vision for the region, how to improve IP awareness, and use of AI
A copyright win for AI firm Anthropic and a new executive order against law firm Jenner & Block were also among the top talking points this week
A principal at Schwegman Lundberg & Woessner explains how AI tools, including DeepIP, can position the firm to help clients
The firm explains why AI-empowered data analytics could make it a more efficient advocate for its clients
Penelope Aspinall, of IP wellbeing charity Jonathan’s Voice, explains why managers should take a three-tiered approach to looking after workers’ mental health
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
Gift this article